Overtreatment of low-risk prostate cancer in the United States: Incidence, cost, complications, and implications for the screening debate.

@article{Gu2013OvertreatmentOL,
  title={Overtreatment of low-risk prostate cancer in the United States: Incidence, cost, complications, and implications for the screening debate.},
  author={Xiangmei Gu and Toni K Choueiri and Neil E. Martin and Jim C. Hu and Paul Linh Nguyen},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 6_suppl},
  pages={161}
}
161 Background: The National Comprehensive Cancer Network (NCCN) recommends active surveillance as the sole option for men with low-risk prostate cancer (LRPC) and a life expectancy <10 years. We sought to describe the incidence, risk factors, cost, and morbidity related to overtreatment of LRPC within the United States. METHODS We used the Surveillance, Epidemiology and End Results (SEER)-Medicare Program to identify 11,744 men ≥66 years with LRPC diagnosed from 2004-2007. Expected survival… CONTINUE READING